Page 101 - Mesenchymal Stem cells, Exosomes and vitamins in the fight aginst COVID

Pain Physician: August 2020 COVID-19 Special Issue 23:S391-S420

RefeRences
1. Elflein J. Coronavirus (COVID-19) in Prevention. [The epidemiological 2019 epidemic and kidneys. Kidney Int
the U.S.-Statistics & Facts. Available characteristics of an outbreak of 2019 2020; 97:824-828.
at: www.statista.com/topics/6084/ novel coronavirus diseases (COVID-19) 22. Wong SH, Lui RN, Sung JJ.
coronavirus -covid -19- in -the - in China]. Zhonghua Liu Xing Bing Xue Covid-19 and the digestive system. J
us/#dossierSummary__chapter2. Za Zhi 2020; 41:145-151. Gastroenterol Hepatol 2020; 35:744-748.
Accessed May 15, 2020. 11. Centers for Disease Control and 23. Li YC, Bai WZ, Hashikawa T. The
2. Cutler DM, Nikpay S, Huckman RS. Prevention. Information for clinicians neuroinvasive potential of SARS-CoV2
The business of medicine in the era of on investigational therapeutics for may play a role in the respiratory
COVID-19. JAMA 2020; 323:2003-2004. patients with COVID-19. Available failure of COVID-19 patients. J Med
3. Jha S, Shah S, Calderon MD, Soin A, at: www.cdc.gov/coronavirus/2019- Virol 2020; 92:552-555.
Manchikanti L. The effect of COVID-19 ncov/hcp/therapeutic-options.html. 24. Tang N, Li D, Wang X, Sun Z. Abnormal
on interventional pain management Accessed May 14, 2020. coagulation parameters are associated
practices: A physician burnout survey. 12. Chen J, Qi T, Liu L, et al. Clinical with poor prognosis in patients with
Pain Physician 2020; 23:S271-S282. progression of patients with COVID-19 novel coronavirus pneumonia. J
4. Shah S, Diwan S, Soin A, et al. in Shanghai, China. J Infect 2020; Thromb Haemost 2020; 18:844-847.
Evidence-based risk mitigation/ 80:e1-e6. 25. Dominici M, Le Blanc K, Mueller I,
stratification during COVID-19 for 13. Wu C, Chen X, Cai Y, et al. Risk factors et al. Minimal criteria for defining
return to Interventional Pain Practice: associated with acute respiratory multipotent mesenchymal stromal
ASIPP Guidelines. Pain Physician 2020; distress syndrome and death in cells. The International Society for
23:S161-S182. patients with coronavirus disease 2019 Cellular Therapy position statement.
5. Richardson S, Hirsch JS, Narasimhan pneumonia in Wuhan, China. JAMA Cytotherapy 2006; 8:315-317.
M, et al. Presenting characteristics, Intern Med 2020; 180:1-11. 26. Rosado-de-Castro PH, Schmidt Fda
comorbidities, and outcomes among 14. Zhou F, Yu T, Du R. Clinical course R, Battistella V, et al. Biodistribution
5700 patients hospitalized with and risk factors for mortality of adult of bone marrow mononuclear cells
COVID-19 in the New York City area. inpatients with COVID-19 in Wuhan, after intra-arterial or intravenous
JAMA 2020; 323:2052-2059. China: A retrospective cohort study. transplantation in subacute stroke
6. Schaller T, Hirschbühl K, Burkhardt Lancet 2020; 395:1054-1062. patients. Regen Med 2013; 8:145-155.
K, et al. Postmortem examination of 15. Wang D, Hu B, Hu C. Clinical 27. Wysoczynski M, Khan A, Bolli R.
patients with COVID-19. JAMA 2020; characteristics of 138 hospitalized New paradigms in cell therapy:
323:2518-2520. patients with 2019 novel coronavirus- Repeated dosing, intravenous delivery,
7. World Health Organization. infected pneumonia in Wuhan, China. immunomodulatory actions, and new
Coronavirus disease 2019 (COVID-19) JAMA 2020; 323:1061-1069. cell types. Circ Res 2018; 123:138-158.
situation report–93. Available 16. Li B, Yang J, Zhao F. Prevalence and 28. Barbosa da Fonseca LM, Xavier
at: www.who.int/docs/default- impact of cardiovascular metabolic SS, Rosado de Castro PH, et al.
source/coronaviruse/situation- diseases on COVID-19 in China. Clin Biodistribution of bone marrow
reports/20200422-sitrep-93-covid-19. Res Cardiol 2020; 109:531-538. mononuclear cells in chronic chagasic
pdf?sfvrsn=35cf80d7_4. Accessed May 17. Oudit GY, Kassiri Z, Jiang C. SARS- cardiomyopathy after intracoronary
13, 2020. coronavirus modulation of myocardial injection. Int J Cardiol 2011;
8. Wu Z, McGoogan JM. Characteristics ACE2 expression and inflammation in 149:310-314.
of and important lessons from the patients with SARS. Eur J Clin Invest 29. Akker F, Feyen D, Hoogen P, et al.
coronavirus disease 2019 (COVID-19) 2009; 39:618-625. Intramyocardial stem cell injection:
outbreak in China: Summary of a 18. Xiong TY, Redwood S, Prendergast Go(ne) with the flow. Eur Heart J 2017;
report of 72314 cases from the Chinese B, Chen M. Coronaviruses and the 38:184-186.
Center for Disease Control and cardiovascular system: Acute and long- 30. Matthay MA, Calfee CS, Zhuo H,
Prevention. JAMA 2020 Feb 24. [Epub term implications. Eur Heart J 2020; et. al. Treatment with allogeneic
ahead of print]. 41:1798-1800. mesenchymal stromal cells for
9. Centers for Disease Control and 19. Chen D, Li X, Song Q, Hu C, Su F, Dai J. moderate to severe acute respiratory
Prevention. Interim clinical guidance Hypokalemia and clinical implications distress syndrome (START Study):
for management of patients with in patients with coronavirus A randomised phase 2a safety trial.
confirmed coronavirus disease disease 2019 (COVID-19) medRxiv Lancet Respir Med 2019; 7:154-162.
(COVID-19). Available at: www.cdc. 2020.02.27.20028530. 31. Henriksson HB, Papadimitriou N,
gov/coronavirus/2019-ncov/ hcp/ 20. Cheng Y, Luo R, Wang K, et al. Kidney Hingert D, Baranto A, Lindahl A, Brisby
clinical-guidance-management- disease is associated with in-hospital H. The traceability of mesenchymal
patients.html. Accessed May 16,2020. death of patients with COVID-19. stromal cells after injection into
10. Epidemiology Working Group for Kidney Int 2020; 97:829-838. degenerated discs in patients with
NCIP Epidemic Response, Chinese 21. Naicker S, Yang CW, Hwang SJ, Liu BC, low back pain. Stem Cells Dev 2019;
Center for Disease Control and Chen JH, Jha V. The novel coronavirus 28:1203-1211.

S418 www.painphysicianjournal.com